Lalmohan Maji

Employment

• SRM Institute of Science and Technology Full time Ph.D. Research Scholar
  2025 - Present
• TARIFA MEMORIAL INSTITUTE OF PHARMACY Assistant professor
  2024 - 2025
• Alkem (India) Trainee officer
  2020 - 2021

Education

• SRM Institute of Science and Technology Doctor of Philosophy (Ph.D.)
  2025 - Present
• Rajiv Gandhi University of Health Sciences Master of pharmacy
  2021 - Present
• Maulana Abul Kalam Azad University of Technology, West Bengal Bachalor of pharmacy
  2016 - 2020

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• Exploration of a Novel Imidazo[4,5-b]pyridine–dihydropyrimidinone hybrids as aurora kinase a inhibitors: integrated pharmacophore modelling, docking and simulation approaches
  Molecular Diversity 2026 DOI: 10.1007/s11030-026-11537-y
  +Save
• Enhancing understanding of phytochemicals’ role in managing metabolic disorders
  Plant-Based Drug Discovery 2026 DOI: 10.1016/b978-0-443-31698-2.00002-3
  +Save
• Exploring tetrazole chemistry: synthetic techniques, structure–activity relationship, and pharmacological insights in antimicrobial and anticancer therapy
  Frontiers in Chemistry 2025 DOI: 10.3389/fchem.2025.1700143
  +Save
• Explanatory review on DDR inhibitors: their biological activity, synthetic route, and structure–activity relationship
  Molecular Diversity 2025 DOI: 10.1007/s11030-024-11091-5
  +Save
• Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance
  European Journal of Medicinal Chemistry 2025 DOI: 10.1016/j.ejmech.2024.117034
  +Save
• Recent advancements in mechanistic research, therapeutic potential, and structure-activity relationships of aurora kinase inhibitors in cancer therapies
  Bioorganic Chemistry 2025 DOI: 10.1016/j.bioorg.2024.107976
  +Save
• Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship
  Molecular Diversity 2024 DOI: 10.1007/s11030-023-10794-5
  +Save
• Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship
  European Journal of Medicinal Chemistry 2024 DOI: 10.1016/j.ejmech.2024.116535
  +Save
• Medicinal Chemistry Perspectives on Recent Advances in Src Kinase Inhibitors as a Potential Target for the Development of Anticancer Agents: Biological Profile, Selectivity, Structure‐Activity Relationship
  Chemistry & Biodiversity 2023 DOI: 10.1002/cbdv.202300515
  +Save
• An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
  Journal of Biomolecular Structure and Dynamics 2023 DOI: 10.1080/07391102.2023.2252082
  +Save